CVS Health Corporation $CVS Shares Bought by Robeco Institutional Asset Management B.V.

Key Points

• Robeco increased its CVS Health stake by 4.1% in the third quarter, acquiring 82,976 additional shares and bringing its holdings to 2.09 million shares valued at approximately $179.2 million. Institutional investors and hedge funds own 80.66% of CVS.
• CVS reported strong quarterly results, with earnings of $2.58 per share and revenue of $106.1 billion, exceeding analyst estimates and increasing revenue 7.3% year over year. Analysts have a consensus “Moderate Buy” rating and an average price target of $107.80.
• The company’s growth opportunities include attracting customers from Walgreens and Rite Aid closures, improving Aetna administration and expanding MinuteClinic locations, while rising medical costs and Medicare Advantage uncertainty remain risks. CVS also declared a quarterly dividend of $0.665 per share, yielding approximately 2.8% annually.

Robeco Institutional Asset Management B.V. grew its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,091,736 shares of the pharmacy operator's stock after acquiring an additional 82,976 shares during the period. Robeco Institutional Asset Management B.V. owned 0.16% of CVS Health worth $179,241,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CVS. BlackRock Inc. acquired a new position in CVS Health in the 2nd quarter worth about $12,747,462,000. State Street Corp increased its holdings in CVS Health by 26.3% in the second quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock worth $7,751,205,000 after buying an additional 15,604,883 shares during the last quarter. Bank of America Corp DE raised its position in CVS Health by 148.0% during the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock valued at $2,398,868,000 after acquiring an additional 13,836,701 shares in the last quarter. Pzena Investment Management LLC bought a new stake in CVS Health in the second quarter worth $1,217,558,000. Finally, Wellington Management Group LLP boosted its holdings in CVS Health by 49.8% in the second quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock worth $3,496,725,000 after purchasing an additional 11,233,381 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Opportunity to gain pharmacy customers: CVS is targeting customers displaced by Walgreens and Rite Aid store closures. The initiative could support prescription volume, retail sales and customer retention if CVS successfully converts those patients. CVS targets former Walgreens, Rite Aid customers after 1,000 stores close
• Positive Sentiment: Aetna administrative improvements: CVS says Aetna is streamlining prior authorizations, approving more than 95% of eligible requests within 24 hours and expanding bundled approvals. Faster decisions could improve member and provider satisfaction while reducing administrative costs. How CVS’ Aetna Is Advancing Efforts to Reduce Administrative Burden
• Positive Sentiment: MinuteClinic expansion: Three new Massachusetts locations—including the first in Boston—expand CVS’s healthcare footprint and may increase patient traffic, service revenue and cross-selling opportunities. MinuteClinic opens three new retail medical clinics
• Neutral Sentiment: Leadership transition: Chief Information Officer Amaresh Siva is leaving CVS to become Alaska Airlines’ chief information technology officer. The departure may create near-term technology and AI execution uncertainty, though it does not directly change CVS’s financial outlook. Alaska Airlines taps CVS Health executive for new technology role
• Negative Sentiment: Industry and valuation concerns: Coverage highlights pressure from rising medical costs across managed care, uncertainty surrounding Medicare Advantage plan availability and technical weakness after CVS raised its outlook. These issues could limit valuation expansion despite the company’s improved earnings guidance. Management raised the bar for CVS Health stock

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Argus boosted their price target on CVS Health from $104.00 to $114.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. Piper Sandler set a $112.00 price objective on CVS Health in a report on Wednesday, September 9th. Cantor Fitzgerald restated a "neutral" rating on shares of CVS Health in a report on Friday, October 9th. Wall Street Zen cut CVS Health from a "strong-buy" rating to a "buy" rating in a research report on Monday. Finally, BMO Capital Markets set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. Twenty research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and an average price target of $107.80.

CVS Health Trading Up 2.3%

Shares of NYSE:CVS opened at $94.77 on Wednesday. The company has a market cap of $121.21 billion, a P/E ratio of 25.07, a P/E/G ratio of 0.86 and a beta of 0.60. The stock's 50-day moving average is $91.70 and its 200-day moving average is $93.49. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be given a $0.6650 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health's dividend payout ratio is currently 70.37%.

About CVS Health

CVS Health Corporation NYSE: CVS is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company's Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.